New Inhaler – Bevespi – Approved for COPD

FDA approves new Dual Bronchodilator – Bevespi

On April 25, 2016, the United States Food and Drug Administration approved a new inhaler called Bevespi Aerosphere™ for long-term maintenance treatment for those with COPD.
Bevespi is a pressurized metered-dose inhaler

Bevespi is a pressurized metered-dose inhaler

  What is Bevespi?  It contains two different bronchodilators that act to relax muscles that wraps around breathing tubes. One medication is called glycopyrrolate – a muscarinic antagonsit – and the other medication is called formoterol – a beta agonist. The two medications are delivered using a unique co-suspension technology. It is to be used twice a day, 12 hours apart. Other Dual Bronchodilator Products Bevespi is the fourth dual bronchodilator in a single device approved in the United States.  Others dual bronchodilators in order of approval by the FDA are: Anoro Ellipta®, Stiolto Respimat®, and Utibron NeoHaler®. Studies show that using two different bronchodilators are more effective in improving how the lungs work and making it easier to breathe than one bronchodilator. It is likely that Bevespi Aerosphere™ will be available in pharmacies later this year.  

Donald A. Mahler, M.D. is Emeritus Professor of Medicine at Geisel School of Medicine at Dartmouth in Hanover, New Hampshire. He works as a pulmonary physician at Valley Regional Hospital in Claremont, NH, where he is Director of Respiratory Services.